Novartis Pharma AG: payments to doctors
Reported under the Physician Payments Sunshine Act for Open Payments program years 2019–2025. Figures group every CMS reporting entity belonging to this corporate parent.
- Total reported
- $13M
- Providers paid
- 553
- Transactions
- 3,041
- Average per transaction
- $4,271
The average per transaction — $4,271 — is the number worth reading. A large total spread across hundreds of thousands of transactions is a company buying a great many modest meals at educational presentations. A large total across few transactions means consulting, speaking or royalty arrangements with a small number of physicians. The totals alone do not distinguish them.
Where the money went
| State | Total reported | Share |
|---|---|---|
| Massachusetts | $3,741,943 | 28.8% |
| Pennsylvania | $2,434,148 | 18.7% |
| New York | $1,198,122 | 9.2% |
| California | $1,059,939 | 8.2% |
| Texas | $757,920 | 5.8% |
| Ohio | $716,378 | 5.5% |
| Florida | $449,085 | 3.5% |
| Oregon | $301,716 | 2.3% |
| North Carolina | $206,448 | 1.6% |
| Nevada | $196,269 | 1.5% |
| Mississippi | $165,639 | 1.3% |
| Tennessee | $146,300 | 1.1% |
| Michigan | $143,718 | 1.1% |
| Minnesota | $138,475 | 1.1% |
| Illinois | $132,713 | 1.0% |
| Connecticut | $111,500 | 0.9% |
| Washington | $103,401 | 0.8% |
| Arizona | $93,253 | 0.7% |
| Missouri | $92,904 | 0.7% |
| Idaho | $91,625 | 0.7% |
| Iowa | $83,729 | 0.6% |
| Maryland | $68,881 | 0.5% |
| Wisconsin | $61,723 | 0.5% |
| Virginia | $61,048 | 0.5% |
| Colorado | $57,413 | 0.4% |
| District of Columbia | $57,105 | 0.4% |
| South Carolina | $50,513 | 0.4% |
| Utah | $49,573 | 0.4% |
| Alabama | $43,544 | 0.3% |
| Georgia | $35,127 | 0.3% |
| Kentucky | $33,298 | 0.3% |
| New Jersey | $23,083 | 0.2% |
| Arkansas | $21,114 | 0.2% |
| West Virginia | $14,875 | 0.1% |
| New Hampshire | $13,599 | 0.1% |
| Hawaii | $7,136 | 0.1% |
| Nebraska | $6,940 | 0.1% |
| Kansas | $6,168 | 0.0% |
| Louisiana | $4,885 | 0.0% |
| Indiana | $3,159 | 0.0% |
| New Mexico | $2,300 | 0.0% |
Products named in Novartis Pharma AG's payments
The drugs and devices most often named as the product a payment related to. A meal at a presentation about a product counts here, so this tracks what the company promotes as much as what it sells.
- BEOVU$661,522
- AIN457F_COSENTYX_IMMUNOLOGY$315,487
- COSENTYX$284,748
- LCZ696B_ENTRESTO_CARDIOVASCULAR$281,769
- BLZ_BEOVU_OPHTHALMOLOGY$253,277
- KESIMPTA$191,460
- ENTRESTO$177,669
- RTH258A_BEOVU_OPHTHALMOLOGY$128,496
- LEQVIO$119,954
- COSENTYX_COSENTYX_DERMATOLOGY$119,214
- GLEEVEC$118,093
- ARZERRA$111,644
- LCZ696D_ENTRESTO_CARDIOVASCULAR$110,063
- SCEMBLIX$103,950
- GLI_GLEEVEC_ONCOLOGY$100,000